Boilerplate clauses

Boilerplate clauses

This subtopic focuses on boilerplate clauses in commercial business-to-business agreements. For information on commercial clauses more generally, see: Commercial clauses—overview.

For information on boilerplate in business-to-consumer contracts, see the section on ‘Consumer boilerplate’ below.

For information on boilerplate in public sector contracts, see the section on ‘Public sector boilerplate’ below.

The role of boilerplate

Lawyers work on a huge variety of transactions, but all of them will in some way involve written agreements. All of those agreements should contain some boilerplate clauses.

‘Boilerplate’ is the term used to describe the clauses that are included in an agreement to deal with the mechanics of how it works and those legal points that are relevant to most transactions. For further consideration of the role and importance of boilerplate clauses, see Practice Note: The role of boilerplate.

Boilerplate clauses are generally found at the beginning and the end of an agreement. Such clauses are often thought of as standard, miscellaneous provisions, but this is a very dangerous view to adopt. It is not unusual for a boilerplate clause to be the cause of litigation. Since a boilerplate clause

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

TAKE A FREE TRIAL

Latest Life Sciences News

UPC won't refer costs questions to top EU court

Law360, London: The Unified Patent Court (UPC) said 20 August 2025 that it cannot refer questions of its framework or procedures to the EU's top court, ruling that such issues fall outside the EU's jurisdiction.

HRA publishes report on legal, policy and ethical use of patient information in research

The Health Research Authority (HRA) has published a report on the legal, policy and ethical issues involved in using patient information to identify and contact individuals about participating in health and care research. The work follows recommendations from Lord O’Shaughnessy’s independent review of commercial clinical trials in the UK, which called for clearer arrangements to help patients hear about research opportunities in ways that are trusted and transparent. In response, the Department of Health and Social Care (DHSC) commissioned the HRA to establish a common approach to contacting patients about research. The report was developed on behalf of partners in the Recovery, Resilience and Growth (RRG) Programme, now part of the UK Clinical Research Delivery (UKCRD) programme. Programme partners will determine which recommendations to take forward and how to prioritise them. The HRA intends to publish detailed guidance to support implementation. It advises that changes to research studies should not be made until this guidance is available.

MedTech Europe calls for simplification of EU digital legislation for medical devices

MedTech Europe has published a position paper proposing targeted reforms to ensure the coherent implementation of EU digital legislation affecting the medical technology sector. The paper responds to the European Commission’s regulatory simplification agenda and outlines recommendations to align horizontal digital laws with existing sector-specific frameworks, namely Regulation (EU) 2017/745, the Medical Devices Regulation (MDR), Regulation (EU) 2017/746, the In Vitro Diagnostic Medical Devices Regulation (IVDR), and Regulation (EU) 2025/327, the European Health Data Space (EHDS).

Life Sciences weekly highlights—28 August 2025

This week's edition of Life Sciences weekly highlights includes an analysis by Covington & Burlington LLP of the MHRA’s statement of policy intent to provide early access to innovative medical devices (Early Access Service) placed on the Great Britain market and a Law360 analysis of the Unified Patent Court’s (UPC) Court of Appeal ruling that questions of the UPC’s framework or procedures are outside the jurisdiction of the European Court of Justice because the UPC agreement is not a directive, regulation or act of the EU. Also included, is news that the Swiss Agency for Therapeutic Products (Swissmedic) has started accepting voluntary registrations of medical devices on swissdamed in advance of mandatory registration; two reports compare regulator approval rates and timelines for new drugs in the US, Japan, Europe and Australia, showing Japan leads with the shortest review times but half of all new drugs are submitted in the US first; the Competition and Markets Authority’s Subsidy Advice Unit accepted a request from the Office for Life Sciences to review its proposed Life Sciences Large Investment Portfolio scheme and the MHRA published guidance on plans to streamline the assessment of some substantial modifications to clinical trial approvals.